| View |
BR-1297_PI_01.pdf
|
BR-1297
|
Dulaglutide
|
Trulicity
|
1.5 mg/0.5 mL
|
Solution For Injection
|
Antidiabetic
|
Eli Lilly and Company
|
United States of America
|
Monitored Release
|
08 October 2019
|
18 June 2025
|
| View |
BR-1299_PI_01.pdf
|
BR-1299
|
Ixekizumab
|
Taltz
|
80mg/mL
|
Solution For Injection (SC)
|
Interleukin Inhibitor
|
Eli Lilly & Company
|
United States of America
|
Monitored Release
|
17 March 2022
|
08 July 2025
|
| View |
BR-1300_PI_01.pdf
|
BR-1300
|
Ixekizumab
|
Taltz
|
80mg/mL
|
Solution For Injection (SC)
|
Interleukin Inhibitor
|
Eli Lilly & Company
|
United States of America
|
Monitored Release
|
17 March 2022
|
08 July 2025
|
| View |
|
BR-1303
|
Hepatitis A (Inactivated) Vaccine (Adsorbed)
|
Havrix 720
|
720 ELISA units/0.5 mL
|
Suspension for Injection (IM)
|
Vaccine
|
GlaxoSmithKline Biologicals SA
|
Belgium
|
Initial (Variation)
|
28 June 2024
|
28 June 2029
|
| View |
|
BR-1304
|
Hepatitis A (Inactivated) Vaccine (Adsorbed)
|
Havrix 1440
|
1440 ELISA units/mL
|
Suspension for Injection (IM)
|
Vaccine
|
GlaxoSmithKline Philippines Inc.
|
Belgium
|
Initial (Variation)
|
24 January 2025
|
24 January 2030
|
| View |
|
BR-1308
|
Pneumococcal Conjugate Vaccine, 13-Valent (adsorbed) [See formulation]
|
Prevenar 13
|
0.5 mL per dose
|
Suspension For Im Injection
|
Vaccine
|
Pfizer Manufacturing Belgium NV
|
Belgium
|
Renewal
|
07 October 2024
|
05 December 2029
|
| View |
|
BR-1316
|
Trastuzumab
|
Herzuma
|
150mg
|
Powder for Concentrate Solution For Infusion (IV)
|
Antineoplastic Agents (Monoclonal Antibodies)
|
Celltrion Inc, Republic of Korea
|
Korea
|
Renewal
|
15 March 2025
|
15 March 2031
|
| View |
|
BR-1317
|
Trastuzumab
|
HERZUMA
|
440mg
|
Powder for Concentrate for Solution fro Infusion (IV)
|
-
|
Celltrion Pharm, Inc.
|
Korea
|
-
|
03 April 2020
|
03 April 2025
|
| View |
BR-1318_PI_01.pdf
|
BR-1318
|
Follitropin Alfa / Lutropin Alfa
|
Pergoveris
|
350 IU/150 IU (0.48mL)
|
Solution For Injection (SC)
|
-
|
Merck Serono S.p.A.
|
Italy
|
-
|
16 April 2020
|
16 April 2025
|
| View |
|
BR-1319
|
Follitropin alfa / Lutropin alfa
|
Pergoveris
|
450 IU/225 IU (0.72 mL)
|
Solution For Injection (SC)
|
-
|
Merck Serono S.p.A
|
Italy
|
Variation
|
11 June 2021
|
16 April 2025
|
| View |
|
BR-1320
|
Follitropin alfa / Lutropin alfa
|
Pergoveris
|
900 IU/450 IU (1.44 mL)
|
Solution For Injection (SC)
|
-
|
Merck Serono S.p.A.
|
Italy
|
Variation
|
11 June 2021
|
16 April 2025
|
| View |
BR-1321_PI_01.pdf
|
BR-1321
|
Botulinum Toxin Type A
|
Nabota
|
200 Units
|
Lyophilized Powder for Solution for Injection (IM/SC)
|
-
|
Daewoong Pharmaceutical Co., Ltd.
|
Korea
|
Monitored Release
|
16 June 2020
|
16 June 2025
|
| View |
BR-1323_PI_01.pdf
|
BR-1323
|
Adalimumab
|
Humira
|
20mg/0.2mL
|
Solution For Injection (SC)
|
-
|
Vetter Pharma-Fertigung GmbH & Co. KG
|
Germany
|
monitored Release
|
24 June 2020
|
24 June 2025
|
| View |
BR-1324_PI_01.pdf
|
BR-1324
|
Somatropin
|
Genotropin GoQuick
|
12 mg/mL
|
Powder and Solvent for Solution for Injection (SC)
|
Anterior Pituitary Lobe Hormones and Analogues
|
Pfizer Manufacturing Belgium N.V.
|
Belgium
|
Monitored Release (MR) (Reconstruction) `
|
22 February 2024
|
16 July 2025
|
| View |
BR-1325_PI_01.pdf
|
BR-1325
|
Somatropin
|
Genotropin GoQuick
|
5.3mg/mL
|
Powder and Solvent for Solution for Injection (SC)
|
Anterior Pituitary Lobe Hormones and Analogues
|
Pfizer Manufacturing Belgium NV
|
Belgium
|
Monitored Release (MR) (Reconstruction) `
|
22 February 2024
|
16 July 2025
|
| View |
BR-1326_PI_01.pdf
|
BR-1326
|
Semaglutide
|
Ozempic
|
1 mg/0.74mL (1.34mg/mL)
|
Solution For Injection (SC)
|
-
|
Novo Nordisk A/S
|
Denmark
|
Monitored Release (Variation)
|
17 November 2022
|
17 November 2027
|
| View |
BR-1327_PI_01.pdf
|
BR-1327
|
Semaglutide
|
Ozempic
|
0.5 mg/0.37 mL (1.34 mg/mL)
|
Solution for Injection (SC)
|
-
|
Novo Nordisk A/S
|
Denmark
|
Monitored Release (Variation)
|
28 October 2022
|
28 October 2027
|
| View |
BR-1328_PI_01.pdf
|
BR-1328
|
Semaglutide
|
Ozempic
|
0.25 mg/0.19 mL (1.34 mg/mL)
|
Solution for Injection
(SC)
|
-
|
Novo Nordisk A/S
|
Denmark
|
-
|
29 September 2020
|
29 September 2025
|
| View |
|
BR-220
|
Rabies Vaccine (Inactivated) (Wistar Strain Rabies)
|
Verorab
|
Formulation:
After reconstitution with 0.5 mL solvent, 1 vial contains:
Rabies virusa, WISTAR Rabies PM/138 1503-3M strain (inactivated)..........................
"Produced in VERO cells
3.25 IUb
|
Powder for Suspension for Injection (IM/ID)
|
Vaccine
|
Sanofi Pasteur SA
|
France
|
Initial (Variation)
|
31 January 2025
|
31 January 2030
|
| View |
|
BR-280
|
Typhoid Polysaccharide Vaccine
|
Typhim Vi
|
Formulation: Each dose (0.5 mL) contains: Purified Vi capsular polysaccharide of Salmonella typhi (Ty2 strain)...................... 25 mcg
|
Solution for Injection (IM/SC)
|
-
|
Sanofi Pasteur
|
France
|
-
|
18 March 2022
|
01 March 2027
|